Eric William Humke
148 works · 3,327 citations · h-index 21
Top works
- Caspase-9 Can Be Activated without Proteolytic Processing
- ICEBERG
- The PYRIN domain: A member of the death domain‐fold superfamily
- A NOD2–NALP1 complex mediates caspase-1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide
- ERICE, a Novel FLICE-activatable Caspase
- The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins
- Activation of caspases triggered by cytochrome c in vitro1
- Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer
- Gli Protein Activity Is Controlled by Multisite Phosphorylation in Vertebrate Hedgehog Signaling
- Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips
- Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
- Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
- Modulation of the PC12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor protein
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
- An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
- Kif3a is necessary for initiation and maintenance of medulloblastoma
- Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
- Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
- Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
- Abstract LB-290: Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.